Abstract:Background Intra-arterial prourokinase has been shown to be a promising thrombolytic agent in patients with acute ischaemic stroke. Given the global shortage of thrombolytics, we aimed to assess the non-inferiority of intravenous recombinant human prourokinase compared with alteplase in patients with acute ischaemic stroke who were ineligible for or who refused endovascular thrombectomy. Methods PROST-2 was a phase 3, open-label, non-inferiority, randomised controlled trial conducted at 61 hospitals in China. Patients older than 18 years with acute ischaemic stroke, who were ineligible for or who refused endovascular thrombectomy, were randomly assigned in a 1:1 ratio within 4·5 h of stroke onset to receive intravenous recombinant human prourokinase (15 mg bolus followed by 20 mg infusion within 30 min) or intravenous alteplase (0·9 mg per kg, maximum dose 90 mg; 10% bolus followed by remainder as infusion over 60 min). The primary efficacy outcome was the proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days, assessed via masked review in the intention-to-treat population, with a non-inferiority margin for the risk ratio of 0·93. The primary safety outcome was the incidence of symptomatic intracranial haemorrhage within 36 h. This trial is registered with ClinicalTrials.gov (NCT05700591) and is now completed. Findings Between Jan 29, 2023, and March 14, 2024, 1552 patients were randomly assigned: 775 received recombinant human prourokinase and 777 received alteplase. The primary outcome of a modified Rankin Scale score of 0 or 1 at 90 days was reached by 558 (72·0%) of 775 patients in the recombinant human prourokinase group versus 534 (68·7%) of 777 in the alteplase group (risk ratio 1·04 [95% CI 0·98 to 1·10]; p<0·0001 for non-inferiority). The frequency of symptomatic intracranial haemorrhage within 36 h was lower in the recombinant human prourokinase group than in the alteplase group (two [0·3%] of 770 patients vs ten [1·3%] of 775, risk difference –1·0 percentage points [95% CI –2·1 to –0·1]; p=0·021), as was the incidence of major bleeding at 7 days (four [0·5%] vs 16 [2·1%]; –1·5 percentage points (–2·8 to –0·4); p=0·0072). All-cause mortality within 7 days did not differ between groups (five [0·6%] deaths in the recombinant human prourokinase group vs 13 [1·7%] in the alteplase group; risk difference –1·0 percentage points; 95% CI –2·3 to 0·1]; p=0·060). Interpretation In our trial, recombinant human prourokinase was shown to be non-inferior to alteplase for achieving excellent functional outcome, with no difference between groups in safety endpoints. These findings support the use of recombinant human prourokinase as a viable alternative to alteplase for patients with ischaemic stroke who are eligible for intravenous thrombolysis therapy but ineligible for or who have refused endovascular thrombectomy. Funding Tasly Biopharmaceuticals, National Key R&D Program of China, National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, and Beijing Municipal Science & Technology Commission. Translation For the Chinese translation of the abstract see Supplementary Materials section.

A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction

Effects of Intracoronary administration of nitroprusside on no-reflow phenomenon during emergency percutaneous coronary Intervention in patients with acute myocardial infarction

The efficacy and safety of pharmacoinvasive therapy with prourokinase for acute ST-segment elevation myocardial infarction patients with expected long percutaneous coronary intervention-related delay.

Effects of Intracoronary Pro-urokinase or Tirofiban on Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Multi-Center, Placebo-Controlled, Single-Blind, Randomized Clinical Trial

Combined Intracoronary Prourokinase Thrombolysis on Myocardial Perfusion and Vascular Endothelial Function in STEMI

Urokinase Combined with Liposomal Alprostadil in the Treatment of Acute Myocardial Infarction

Efficacy and Safety of a Pharmaco-Invasive Strategy Using Half-Dose Recombinant Human Prourokinase in Patients with ST-Segment Elevation Myocardial Infarction During Hospitalization

Comparison of the clinical efficacy of primary percutaneous coronary intervention with thrombolytic therapy for acute myocardial infarction

Efficacy and Safety of a Pharmaco-Invasive Strategy with Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment–Elevation Myocardial Infarction

[Myocardial Protection of Remote Ischemic Postconditioning During Primary Percutaneous Coronary Intervention in Patients with Acute ST-segment Elevation Myocardial Infarction].

Single Bolus r-SAK Before Primary PCI for ST-Segment–Elevation Myocardial Infarction

Evaluation of the efficacy and safety of recombinant prourokinase in patients with acute myocardial infarction

Prognosis in Patients with ST-Segment Elevation Myocardial Infarction Reperfused by PHDP: 1-Year MACEs Follow-Up

Clinical Investigation of Effects of Intravenous Versus Intra-Coronary Injection of Tirofiban During Primary Pci

Clinic Study of Domestic Tirofiban During Primary Percutaneous Coronary Intervention

[Efficacy and safety comparison between pro-urokinase and reteplase in the treatment of patients with acute ST elevation myocardial infarction]

Safety and efficacy of intracoronary tirofiban injection in patients with STEMI before primary PCI

Safety and Efficacy of Intravenous Recombinant Human Prourokinase for Acute Ischaemic Stroke Within 4·5 H after Stroke Onset (PROST-2): a Phase 3, Open-Label, Non-Inferiority, Randomised Controlled Trial

To explore clinical use of thrombus aspiration and platelet glycoprotein Ⅱb/Ⅲa receptor antagonists during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction patients

Intracoronary thrombolysis combined with drug balloon angioplasty in a young ST-segment elevation myocardial infarction patient: A case report

Remote Ischaemic Preconditioning Reduces Myocardial Ischaemic Reperfusion Injury in Patients with St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention